Amgen's Third Quarter 2013 Revenues Increased 10 Percent to $4.7 Billion and Adjusted Earnings Per Share (EPS) Increased 16 Percent to $1.94

THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire via COMTEX/ -- Amgen /quotes/zigman/19815/quotes/nls/amgn AMGN -1.02% today announced results for the third quarter of 2013. Key financial results for the quarter include:

-- Total revenues increased 10 percent to $4,748 million, with 11 percent product sales growth driven by strong performance across the portfolio, particularly from Neulasta® (pegfilgrastim), Enbrel® (etanercept), Prolia® (denosumab) and XGEVA® (denosumab). Product sales included a $155 million order for NEUPOGEN® (filgrastim) from the U.S. government.

Help employers find you! Check out all the jobs and post your resume.